サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655569

生物学的製剤の世界市場

Biological Drugs

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
生物学的製剤の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生物学的製剤の世界市場は2030年までに6,344億米ドルに達する見込み

2024年に3,763億米ドルと推定される生物学的製剤の世界市場は、2024年から2030年にかけてCAGR 9.1%で成長し、2030年には6,344億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである治療用タンパク質は、CAGR 10.3%を記録し、分析期間終了時には2,891億米ドルに達すると予想されます。モノクローナル抗体セグメントの成長率は、分析期間中CAGR 8.3%と推定されます。

米国市場は1,061億米ドルと推定、中国はCAGR 8.4%で成長予測

米国の生物学的製剤市場は、2024年に1,061億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに962億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.4%と7.2%と予測されています。欧州では、ドイツがCAGR 7.3%で成長すると予測されています。

世界の生物学的製剤市場- 主要動向と促進要因のまとめ

生物学的製剤が従来の医薬品と異なる点とは？

生物学的製剤、または生物製剤は、細胞、組織、組換えDNA技術など、生体由来の治療薬という明確な分類を表しています。化学的に合成される従来の医薬品とは異なり、生物学的製剤は細胞レベルあるいは分子レベルで特定の疾病メカニズムを標的とする巨大で複雑な分子です。これらの医薬品は、高度に標的化された効果的な治療法を提供することにより、がん、自己免疫疾患、糖尿病などの慢性疾患の治療を一変させました。生物製剤は精密医療の最前線にもあり、個人の遺伝的体質に合わせた治療を可能にすることで、治療効果を高め、副作用を軽減しています。

研究開発パイプラインは、生物学的製剤の将来をどのように形作るのか？

生物学的製剤市場は、特にモノクローナル抗体、遺伝子治療、治療用タンパク質において、大きな技術革新を目の当たりにしています。新しい生物製剤は、特に腫瘍学、神経学、希少遺伝子疾患などの分野で、満たされていない医療ニーズに対応するために開発されています。CRISPRやCAR-T療法を含むバイオテクノロジーの開発により、疾患経路の修正や欠陥遺伝子の修復も可能な個別化生物製剤の開発が可能となっています。開発パイプラインにある生物製剤の数の増加は、連続バイオプロセスなどの製造技術の進歩と相まって、生物製剤を大規模に生産することを容易にしており、これは将来、世界のヘルスケアニーズに応える鍵となると思われます。

生物学的製剤の採用はヘルスケアシステムにどのような影響を与えているか？

慢性疾患や生命を脅かす疾患の治療に生物学的製剤が普及するにつれ、生物学的製剤はヘルスケア提供システムを再構築しつつあります。しかし、バイオ医薬品は高価であるため、特に新興国市場においては、購入しやすさ、入手しやすさという点で課題があります。これに対処するため、バイオシミラー（基本的には、生物学的製剤の安価で類似性の高いバージョン）が普及しつつあります。バイオシミラーのイントロダクションより、ヘルスケア全体の負担が軽減され、救命治療がより多くの人々にとって利用しやすくなると期待されています。バイオシミラーの承認と市場参入を促進するために、規制の枠組みは進化しており、バイオシミラー市場の価格決定と競争に大きな影響を与える可能性があります。

生物学的製剤の拡大において、規制当局の承認はどのような役割を果たすのか？

生物学的製剤の規制状況は、市場成長の重要な要因です。厳しい承認プロセスは、生物製剤が最高の安全性と有効性基準を満たすことを保証するものであり、医薬品メーカーにとっては長期的で費用のかかる取り組みとなります。しかし、米国FDAや欧州医薬品庁（EMA）などの規制機関が生物学的製剤とバイオシミラーの両方の承認経路を合理化するにつれて、特に希少疾患やアンメット・メディカル・ニーズを対象とする医薬品の承認ペースが高まっています。希少疾病用医薬品や画期的治療薬に対する有利な規制や迅速な承認プロセスは、革新的な生物製剤をより迅速に市場に投入するのに役立っており、この分野全体の拡大に寄与しています。

生物学的製剤市場の成長は、慢性疾患の蔓延、精密医療の台頭、バイオテクノロジー研究の進歩など、いくつかの要因によってもたらされます。より少ない副作用でより効果的な治療を提供する個別化治療に対する需要の高まりは、主要な促進要因です。さらに、希少かつ複雑な疾患に対する新規生物製剤の承認と、生物製剤の研究開発を支援する政府の有利な政策が、市場の拡大を後押ししています。また、バイオシミラーの台頭も重要な役割を果たしています。バイオシミラーは、市場へのアクセスを向上させ、治療費を削減することで、生物製剤セグメントの成長をさらに促進するものと考えられるからです。

セグメント

製品タイプ（治療用タンパク質、モノクローナル抗体、ワクチン）

調査対象企業の例（注目の46社）

  • Abbott Laboratories
  • Amgen, Inc.
  • Baxter International, Inc.
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP16210

Global Biological Drugs Market to Reach US$634.4 Billion by 2030

The global market for Biological Drugs estimated at US$376.3 Billion in the year 2024, is expected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2024-2030. Therapeutic Protein, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$289.1 Billion by the end of the analysis period. Growth in the Monoclonal Antibody segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$106.1 Billion While China is Forecast to Grow at 8.4% CAGR

The Biological Drugs market in the U.S. is estimated at US$106.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$96.2 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global Biological Drugs Market - Key Trends & Drivers Summarized

What Sets Biological Drugs Apart from Traditional Pharmaceuticals?

Biological drugs, or biologics, represent a distinct class of therapies derived from living organisms, including cells, tissues, or recombinant DNA technology. Unlike conventional pharmaceuticals, which are chemically synthesized, biologics are large, complex molecules that target specific disease mechanisms at a cellular or molecular level. These drugs have transformed the treatment of chronic conditions such as cancer, autoimmune diseases, and diabetes by offering highly targeted, effective therapies. Biologics are also at the forefront of precision medicine, enabling treatments to be tailored to an individual’s genetic makeup, which enhances therapeutic outcomes and reduces side effects.

How Is the R&D Pipeline Shaping the Future of Biological Drugs?

The biological drugs market is witnessing significant innovation, particularly in monoclonal antibodies, gene therapies, and therapeutic proteins. New biologics are being developed to address unmet medical needs, especially in areas like oncology, neurology, and rare genetic disorders. Advances in biotechnology, including CRISPR and CAR-T therapies, are allowing for the development of personalized biologics that can modify disease pathways or even repair defective genes. The growing number of biologics in the development pipeline, coupled with advances in manufacturing techniques like continuous bioprocessing, is making it easier to produce biologics at scale, which will be key to meeting global healthcare needs in the future.

How Is the Adoption of Biological Drugs Impacting Healthcare Systems?

As biologics become more prevalent in treating chronic and life-threatening diseases, they are reshaping healthcare delivery systems. However, their high cost has led to challenges in terms of affordability and accessibility, particularly in developing markets. To address this, biosimilars—essentially, cheaper, highly similar versions of biologic drugs—are gaining traction. The introduction of biosimilars is expected to reduce the overall healthcare burden and make these life-saving treatments more accessible to a broader population. Regulatory frameworks are evolving to facilitate the approval and market entry of biosimilars, which could significantly influence pricing dynamics and competition in the biological drugs market.

What Role Does Regulatory Approval Play in the Expansion of Biological Drugs?

The regulatory landscape for biological drugs is a critical factor in market growth. Stringent approval processes ensure that biologics meet the highest safety and efficacy standards, which can be a lengthy and expensive endeavor for drug manufacturers. However, as regulatory bodies such as the U.S. FDA and European Medicines Agency (EMA) streamline pathways for both biologics and biosimilars, the pace of approvals has increased, particularly for drugs targeting rare diseases and unmet medical needs. Favorable regulations and accelerated approval processes for orphan drugs and breakthrough therapies are helping to bring innovative biologics to market more quickly, contributing to the overall expansion of this sector.

The growth in the biological drugs market is driven by several factors, including the increasing prevalence of chronic diseases, the rise of precision medicine, and advancements in biotechnological research. The growing demand for personalized therapies that offer more effective treatment with fewer side effects is a major driver. Additionally, the approval of novel biologics for rare and complex conditions, along with favorable government policies supporting biologics R&D, is boosting market expansion. The rise of biosimilars is also playing a critical role, as they are poised to increase market accessibility and reduce treatment costs, thereby further driving growth in the biologics segment.

SCOPE OF STUDY:

The report analyzes the Biological Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Therapeutic Protein, Monoclonal Antibody, Vaccine)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • Amgen, Inc.
  • Baxter International, Inc.
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Biological Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Driving Demand for Biological Drugs
    • Advancements in Biotechnological Research and Drug Development
    • Growing Adoption of Biologics in Oncology and Autoimmune Disease Treatments
    • Increased Focus on Personalized Medicine and Targeted Therapies
    • Regulatory Support for Biosimilars Expanding Access to Biological Drugs
    • Technological Innovations in Bioprocessing Improving Drug Production
    • Rising Investments in R&D by Biopharma Companies
    • Impact of Expiring Patents on Biologics and Growth of Biosimilars
    • Global Expansion of Healthcare Infrastructure Supporting Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biological Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biological Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biological Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biological Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Therapeutic Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Therapeutic Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Therapeutic Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Monoclonal Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: USA 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Canada 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • JAPAN
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: Japan 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • CHINA
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: China 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • EUROPE
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Biological Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Biological Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Biological Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • FRANCE
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: France 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • GERMANY
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Germany 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Italy 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: UK 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Rest of Europe 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biological Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Asia-Pacific 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Biological Drugs by Product Type - Therapeutic Protein, Monoclonal Antibody and Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Rest of World 15-Year Perspective for Biological Drugs by Product Type - Percentage Breakdown of Value Sales for Therapeutic Protein, Monoclonal Antibody and Vaccine for the Years 2015, 2025 & 2030

IV. COMPETITION